Excess Copper Chelating Therapy for Wilson Disease Induces Anemia and Liver Dysfunction

被引：11

作者：

Harada, Masaru ^{[1
]}

Miyagawa, Koichiro ^{[1
]}

Honma, Yuichi ^{[1
]}

Hiura, Masaaki ^{[1
]}

Shibata, Michihiko ^{[1
]}

Matsuhashi, Toru ^{[1
]}

Abe, Shintaro ^{[1
]}

Harada, Riko ^{[1
]}

Tabaru, Akinari ^{[1
]}

机构：

[1] Univ Occupat & Environm Hlth, Japan Sch Med, Dept Internal Med 3, Tokyo, Japan

来源：

INTERNAL MEDICINE | 2011年 / 50卷 / 14期

关键词：

ceruloplasmin; chelating therapy; hemochromatosis; Wilson disease; ACQUIRED SIDEROBLASTIC ANEMIA; LATE ENDOSOMES; IRON; GENE; CERULOPLASMIN; ATP7B; ACERULOPLASMINEMIA; FERROPORTIN; DIAGNOSIS; HEPCIDIN;

D O I：

10.2169/internalmedicine.50.5209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 37-year-old man was diagnosed with Wilson disease at the age of 14. His first manifestations were neurological. He was treated with trientine for more than 10 years and suffered from anemia and liver dysfunction. Wilson disease is a genetic disorder characterized by accumulation of copper in the body. Excess copper is toxic, but copper is an essential trace element. Copper-binding ceruloplasmin is important for iron metabolism. Excess copper chelating treatment-induced anemia and iron deposition in the liver was suspected. Proper monitoring of copper status is important for the management of Wilson disease.

引用

页码：1461 / 1464

页数：4

共 50 条

[1] Hemolytic Anemia Associated With Liver Dysfunction in Wilson Disease
Hassam, Tanveer
Dinani, Amreen
CHEST, 2017, 152 (04) : 251A - 251A
[2] Cell therapy to remove excess copper in Wilson's disease
Gupta, Sanjeev
HUMAN DISORDERS OF COPPER METABOLISM II, 2014, 1315 : 70 - 80
[3] Hypopituitarism in Wilson's disease resolved after copper-chelating therapy
Dauth, Nina
Muecke, Victoria T.
Muecke, Marcus M.
Lange, Christian M.
Welker, Martin
Zeuzem, Stefan
Badenhoop, Klaus
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2021,
[4] Targeting of glycoconjugates to hepatic cells for copper chelating therapy related to Wilson's disease.
Monestier, M.
Rivaux, C.
Gateau, C.
Delangle, P.
Monestier, M.
Renaudet, O.
Charbonnier, P.
Cuillel, M.
Mintz, E.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2014, 19 : S635 - S635
[5] Consequences of chelating therapy discontinuation in Wilson's disease
Kozic, D
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S323 - S323
[6] Improvement of cardiovascular autonomic dysfunction following anti–copper therapy in Wilson’s disease
K. Deguchi
I. Sasaki
T. Touge
M. Tsukaguchi
K. Ikeda
M. Shimamura
Y. Urai
S. Watanabe
H. Takeuchi
S. Kuriyama
Journal of Neurology, 2005, 252 : 495 - 497
[7] Chelating polymeric particles intended for the therapy of Wilson's disease
Skodova, Michaela
Kucka, Jan
Vetrik, Miroslav
Skopal, Jan
Walterova, Zuzana
Sedlacek, Ondrej
Stepanek, Petr
Mattova, Jana
Pouckova, Pavia
Urbanek, Petr
Hruby, Martin
REACTIVE & FUNCTIONAL POLYMERS, 2013, 73 (11): : 1426 - 1431
[8] Iron and Copper Liver Concentrations in Wilson Disease
Day, Patrick L.
Fyffe-Freil, Ria
Vanderboom, Patrick
Spears, Grant
Wangensteen, Kirk J.
Bornhorst, Joshua
Hassan, Sara
Jannetto, Paul J.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2024, 33 (04) : 517 - 523
[9] Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease
Deguchi, K
Sasaki, I
Touge, T
Tsukaguchi, M
Ikeda, K
Shimamura, M
Urai, Y
Watanabe, S
Takeuchi, H
Kuriyama, S
JOURNAL OF NEUROLOGY, 2005, 252 (04) : 495 - 497
[10] Hyaluronate/black phosphorus complexes as a copper chelating agent for Wilson disease treatment
Kim, Seong-Jong
Han, Hye Hyeon
Hahn, Sei Kwang
BIOMATERIALS RESEARCH, 2021, 25 (01)

← 1 2 3 4 5 →